PHARMACOPSYCHIATRY

Scope & Guideline

Exploring the Synergy of Mind and Medicine.

Introduction

Welcome to your portal for understanding PHARMACOPSYCHIATRY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0176-3679
PublisherGEORG THIEME VERLAG KG
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 1984 to 2024
AbbreviationPHARMACOPSYCHIATRY / Pharmacopsychiatry
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRUDIGERSTR 14, D-70469 STUTTGART, GERMANY

Aims and Scopes

The journal 'PHARMACOPSYCHIATRY' focuses on the intersection of pharmacology and psychiatry, emphasizing the importance of therapeutic drug monitoring, pharmacogenetics, and innovative treatment approaches in psychiatric care.
  1. Pharmacotherapy in Psychiatry:
    The journal covers a wide range of pharmacological treatments for psychiatric disorders, including antidepressants, antipsychotics, mood stabilizers, and emerging therapies such as cannabinoids and psychedelics.
  2. Therapeutic Drug Monitoring (TDM):
    A core area of focus is on therapeutic drug monitoring, which assesses drug levels in patients to optimize treatment efficacy and minimize adverse effects, particularly in vulnerable populations such as children and those with complex psychiatric conditions.
  3. Pharmacogenetics and Personalized Medicine:
    The journal emphasizes the role of pharmacogenetics in tailoring psychiatric treatments based on individual genetic profiles, thereby enhancing treatment outcomes and reducing the risk of adverse drug reactions.
  4. Innovative Treatment Approaches:
    Research on novel treatment modalities, including the use of medical cannabis, psychedelics, and non-dopaminergic therapies, reflects a commitment to exploring cutting-edge strategies in psychiatric care.
  5. Epidemiological Studies and Clinical Trials:
    The journal publishes findings from epidemiological studies and clinical trials that inform clinical practices and guidelines, particularly in relation to the pharmacological treatment of psychiatric disorders.
The journal has identified several emerging themes that align with contemporary challenges and advancements in psychiatry, reflecting the evolving landscape of mental health treatment.
  1. Impact of COVID-19 on Psychiatric Treatment:
    Recent publications have increasingly focused on the implications of COVID-19 for psychiatric care, including the effects of antidepressants on COVID-19 prognosis and the mental health challenges arising from the pandemic.
  2. Integration of Cannabinoids in Psychiatry:
    There is a growing body of research exploring the role of cannabinoids in treating various psychiatric conditions, reflecting a trend towards integrating alternative and complementary therapies into mainstream psychiatric practice.
  3. Advancements in Therapeutic Drug Monitoring:
    Research on therapeutic drug monitoring is expanding, with a focus on developing guidelines and protocols for specific populations, such as children, pregnant women, and patients with complex medical histories.
  4. Psychedelic Research as a Treatment Paradigm:
    The exploration of psychedelics as therapeutic agents in psychiatry is gaining momentum, with increasing interest in their potential benefits for conditions like depression and PTSD, marking a significant shift in treatment paradigms.
  5. Pharmacogenetics and Personalized Treatment Strategies:
    The emphasis on pharmacogenetics is on the rise, with studies investigating how genetic variations affect drug metabolism and response, paving the way for more personalized treatment approaches in psychiatry.

Declining or Waning

While 'PHARMACOPSYCHIATRY' continues to explore various themes, certain areas have shown a decline in focus, possibly reflecting shifts in research priorities or clinical practice.
  1. Traditional Antidepressant Approaches:
    Over recent years, there has been a noticeable decrease in studies focused exclusively on traditional antidepressant therapies, such as SSRIs and SNRIs, as more attention shifts towards innovative treatments and personalized medicine.
  2. Longitudinal Studies on Lithium Use:
    The interest in lithium therapy appears to be waning, as evidenced by fewer publications regarding its use in contemporary psychiatric practice, possibly due to the rise of newer medications and treatment modalities.
  3. Generalized Approaches to Psychotropic Medications:
    There is a declining emphasis on generalized or non-specific approaches to psychotropic medications, with a shift towards more targeted and individualized treatment strategies based on pharmacogenetic and biomarker research.

Similar Journals

CLINICAL THERAPEUTICS

Transforming therapeutic strategies through rigorous research.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

JOURNAL OF PSYCHOPHARMACOLOGY

Transforming Understanding of Psychopharmacological Effects
Publisher: SAGE PUBLICATIONS LTDISSN: 0269-8811Frequency: 12 issues/year

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

Journal of Pharmaceutical Health Care and Sciences

Bridging disciplines to elevate pharmaceutical practices.
Publisher: BMCISSN: 2055-0294Frequency: 1 issue/year

The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Elevating Standards in Drug Safety and Efficacy
Publisher: WILEYISSN: 0306-5251Frequency: 12 issues/year

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Connecting researchers and practitioners in the world of pharmacology.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Current Drug Safety

Bridging Research and Real-World Drug Safety Solutions
Publisher: BENTHAM SCIENCE PUBLISSN: 1574-8863Frequency: 3 issues/year

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

DRUGS & THERAPY PERSPECTIVES

Exploring Innovative Pathways in Drug Efficacy
Publisher: SPRINGERNATUREISSN: 1172-0360Frequency: 12 issues/year

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Fostering Insights in Pharmacology and Toxicology for Better Health
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Expert Review of Clinical Pharmacology

Empowering clinicians with the latest in pharmacological advancements.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Exploring the forefront of cardiovascular therapies and research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0160-2446Frequency: 12 issues/year

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.